• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视网膜母细胞瘤1(Rb1)及其抑制靶点S期激酶相关蛋白2(Skp2)的缺失在小鼠胚胎发育过程中具有合成致死性。

Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.

作者信息

Zhao Hongling, Wang Hongbo, Bauzon Frederick, Lu Zhonglei, Fu Hao, Cui Jinhua, Zhu Liang

机构信息

From the Department of Developmental and Molecular Biology, and Ophthalmology & Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461.

From the Department of Developmental and Molecular Biology, and Ophthalmology & Visual Sciences, and Medicine, The Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461

出版信息

J Biol Chem. 2016 May 6;291(19):10201-9. doi: 10.1074/jbc.M116.718049. Epub 2016 Mar 10.

DOI:10.1074/jbc.M116.718049
PMID:26966181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4858970/
Abstract

Tumor suppressor pRb represses Skp2, a substrate-recruiting subunit of the SCF(Skp2) ubiquitin ligase. Rb1(+/-) mice incur "two-hit" pituitary tumorigenesis; Skp2(-/-);Rb1(+/-) mice do not. Rb1(-/-) embryos die on embryonic day (E) 14.5-15.5. Here, we report that Skp2(-/-);Rb1(-/-) embryos died on E11.5, establishing an organismal level synthetic lethal relationship between Rb1 and Skp2 On E10.5, Rb1(-/-) placentas showed similarly active proliferation and similarly inactive apoptosis as WT placenta, whereas Rb1(-/-) embryos showed ectopic proliferation without increased apoptosis in the brain. Combining Skp2(-/-) did not reduce proliferation or increase apoptosis in the placentas but induced extensive apoptosis in the brain. We conditionally deleted Rb1 in neuronal lineage with Nes-Cre and reproduced the brain apoptosis in E13.5 Nes-Cre;Rb1(lox/lox);Skp2(-/-) embryos, demonstrating their synthetic lethal relationship at a cell autonomous level. Nes-Cre-mediated Rb1 deletion increased expression of proliferative E2F target genes in the brains of Skp2(+/+) embryos; the increases rose higher with activation of expression of apoptotic E2F target genes in Skp2(-/-) embryos. The brain apoptosis was independent of p53 but coincident with proliferation. The highly activated expression of proliferative and apoptotic E2F target genes subsided with gradually reduced roles of Skp2 in preventing p27 protein accumulation in the brain in late gestation, allowing the embryos to reach full term with normally sized brains. These findings establish that Rb1 and Skp2 deletions are synthetic lethal and suggest how this lethal relationship might be circumvented, which could help design better therapies for pRb-deficient cancer.

摘要

肿瘤抑制因子pRb可抑制Skp2,Skp2是SCF(Skp2)泛素连接酶的底物招募亚基。Rb1(+/-)小鼠会发生“两次打击”的垂体肿瘤发生;而Skp2(-/-);Rb1(+/-)小鼠则不会。Rb1(-/-)胚胎在胚胎期(E)14.5 - 15.5天死亡。在此,我们报告Skp2(-/-);Rb1(-/-)胚胎在E11.5天死亡,确立了Rb1和Skp2在机体水平上的合成致死关系。在E10.5天,Rb1(-/-)胎盘显示出与野生型胎盘相似的活跃增殖和相似的不活跃凋亡,而Rb1(-/-)胚胎在大脑中显示出异位增殖且凋亡未增加。联合缺失Skp2并未降低胎盘的增殖或增加凋亡,但在大脑中诱导了广泛的凋亡。我们用Nes-Cre在神经谱系中条件性删除Rb1,并在E13.5天的Nes-Cre;Rb1(lox/lox);Skp2(-/-)胚胎中重现了大脑凋亡,证明了它们在细胞自主水平上的合成致死关系。Nes-Cre介导的Rb1缺失增加了Skp2(+/ +)胚胎大脑中增殖性E2F靶基因的表达;在Skp2(-/-)胚胎中,随着凋亡性E2F靶基因表达的激活,这种增加更为显著。大脑凋亡独立于p53但与增殖同时发生。在妊娠后期,随着Skp2在阻止大脑中p27蛋白积累方面的作用逐渐减弱,增殖性和凋亡性E2F靶基因的高度激活表达减弱,使胚胎能够足月出生,大脑大小正常。这些发现确立了Rb1和Skp2缺失是合成致死的,并提示了这种致死关系可能如何被规避,这有助于为pRb缺陷型癌症设计更好的治疗方法。

相似文献

1
Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.视网膜母细胞瘤1(Rb1)及其抑制靶点S期激酶相关蛋白2(Skp2)的缺失在小鼠胚胎发育过程中具有合成致死性。
J Biol Chem. 2016 May 6;291(19):10201-9. doi: 10.1074/jbc.M116.718049. Epub 2016 Mar 10.
2
Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.Skp2 对于异常增殖的 Rb1 缺失细胞的存活以及 Rb1+/- 小鼠的肿瘤发生是必需的。
Nat Genet. 2010 Jan;42(1):83-8. doi: 10.1038/ng.498. Epub 2009 Dec 6.
3
Targeted Inhibition of the E3 Ligase SCF Has Antitumor Activity in -Deficient Human and Mouse Small-Cell Lung Cancer.靶向抑制 E3 连接酶 SCF 在 -缺陷的人类和小鼠小细胞肺癌中具有抗肿瘤活性。
Cancer Res. 2020 Jun 1;80(11):2355-2367. doi: 10.1158/0008-5472.CAN-19-2400. Epub 2020 Apr 7.
4
Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.Skp2 通过限制 E2F1 的活性来抑制 Rb1 缺失肿瘤中的细胞凋亡。
Nat Commun. 2014 Mar 17;5:3463. doi: 10.1038/ncomms4463.
5
Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.在 pRb 缺失后竞相阻止肿瘤发生:一种无害的点突变通过合成致死获得胜利。
Cell Cycle. 2010 Jun 1;9(11):2118-23. doi: 10.4161/cc.9.11.11726.
6
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.针对无法靶向的目标:RB1 缺陷型肿瘤易受 Skp2 泛素连接酶抑制的影响。
Br J Cancer. 2022 Oct;127(6):969-975. doi: 10.1038/s41416-022-01898-0. Epub 2022 Jun 25.
7
p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.p27T187A基因敲入鉴定出用于晚期前列腺癌的Skp2/Cks1口袋抑制剂。
Oncogene. 2017 Jan 5;36(1):60-70. doi: 10.1038/onc.2016.175. Epub 2016 May 16.
8
Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects.靶向抑制 S 期激酶相关蛋白 2(SKP2)介导的细胞周期调控在肺和其他 RB 相关癌症中的作用:对当前现状和未来前景的简要综述。
Adv Biol Regul. 2023 May;88:100964. doi: 10.1016/j.jbior.2023.100964. Epub 2023 Mar 14.
9
SKP2 Knockout in Rb1/p53-Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis.SKP2 敲除在骨肉瘤 Rb1/p53 缺陷型小鼠模型中诱导免疫浸润,并驱动具有有利预后的转录程序。
Mol Cancer Ther. 2024 Feb 1;23(2):223-234. doi: 10.1158/1535-7163.MCT-23-0173.
10
Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.在小鼠视网膜祖细胞中同时删除Pten和Rb会导致完全显性的双侧视网膜母细胞瘤。
Mol Cancer. 2015 Apr 24;14:93. doi: 10.1186/s12943-015-0360-y.

引用本文的文献

1
Distinct outcomes from targeted perturbations of the multi-subunit SCF E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis.多亚基SCF E3泛素连接酶靶向扰动在阻断Trp53/Rb1基因缺失的前列腺肿瘤发生中的不同结果。
Commun Biol. 2025 Feb 22;8(1):278. doi: 10.1038/s42003-025-07662-3.
2
Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy.RB1基因缺陷型癌症的治疗策略:基因调控与靶向治疗的交叉点
Cancers (Basel). 2024 Apr 19;16(8):1558. doi: 10.3390/cancers16081558.
3
Targeted inhibition of SCF confers anti-tumor activities resulting in a survival benefit in osteosarcoma.靶向抑制干细胞因子可发挥抗肿瘤活性,从而带来骨肉瘤的生存获益。
Oncogene. 2024 Mar;43(13):962-975. doi: 10.1038/s41388-024-02942-4. Epub 2024 Feb 14.
4
SKP2 Knockout in Rb1/p53-Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis.SKP2 敲除在骨肉瘤 Rb1/p53 缺陷型小鼠模型中诱导免疫浸润,并驱动具有有利预后的转录程序。
Mol Cancer Ther. 2024 Feb 1;23(2):223-234. doi: 10.1158/1535-7163.MCT-23-0173.
5
Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients.使用来自细胞系和患者的多组学数据预测 DNA 损伤修复、染色质重塑和细胞周期中的合成致死性。
Sci Rep. 2023 Apr 29;13(1):7049. doi: 10.1038/s41598-023-34161-4.
6
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.针对无法靶向的目标:RB1 缺陷型肿瘤易受 Skp2 泛素连接酶抑制的影响。
Br J Cancer. 2022 Oct;127(6):969-975. doi: 10.1038/s41416-022-01898-0. Epub 2022 Jun 25.
7
Targeted Inhibition of the E3 Ligase SCF Has Antitumor Activity in -Deficient Human and Mouse Small-Cell Lung Cancer.靶向抑制 E3 连接酶 SCF 在 -缺陷的人类和小鼠小细胞肺癌中具有抗肿瘤活性。
Cancer Res. 2020 Jun 1;80(11):2355-2367. doi: 10.1158/0008-5472.CAN-19-2400. Epub 2020 Apr 7.
8
Cells Lacking the Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.缺乏肿瘤抑制基因的细胞对 Aurora B 激酶的依赖性很高,以维持其存活。
Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29.

本文引用的文献

1
Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.Skp2 通过限制 E2F1 的活性来抑制 Rb1 缺失肿瘤中的细胞凋亡。
Nat Commun. 2014 Mar 17;5:3463. doi: 10.1038/ncomms4463.
2
Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors.Skp2 缺失会暴露出一种 p27 保护机制,该机制可以在没有 pRb 和 p53 肿瘤抑制因子的情况下阻止肿瘤发生。
Cancer Cell. 2013 Nov 11;24(5):645-59. doi: 10.1016/j.ccr.2013.09.021.
3
E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells.E2f1-3 从祖细胞中的激活因子转变为分化细胞中的抑制因子。
Nature. 2009 Dec 17;462(7275):930-4. doi: 10.1038/nature08677.
4
Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.Skp2 对于异常增殖的 Rb1 缺失细胞的存活以及 Rb1+/- 小鼠的肿瘤发生是必需的。
Nat Genet. 2010 Jan;42(1):83-8. doi: 10.1038/ng.498. Epub 2009 Dec 6.
5
Deregulated E2f-2 underlies cell cycle and maturation defects in retinoblastoma null erythroblasts.视网膜母细胞瘤缺失型成红细胞中E2f-2失调是细胞周期和成熟缺陷的基础。
Mol Cell Biol. 2007 Dec;27(24):8713-28. doi: 10.1128/MCB.01118-07. Epub 2007 Oct 8.
6
A Skp2 autoinduction loop and restriction point control.一种Skp2自诱导环与限制点控制。
J Cell Biol. 2007 Aug 27;178(5):741-7. doi: 10.1083/jcb.200703034.
7
Rb is critical in a mammalian tissue stem cell population.视网膜母细胞瘤蛋白在哺乳动物组织干细胞群体中至关重要。
Genes Dev. 2007 Jan 1;21(1):85-97. doi: 10.1101/gad.1485307.
8
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit.视网膜母细胞瘤蛋白与后期促进复合体在细胞周期退出过程中发生物理相互作用并在功能上协同作用。
Nat Cell Biol. 2007 Feb;9(2):225-32. doi: 10.1038/ncb1532. Epub 2006 Dec 24.
9
F-box protein Skp2: a novel transcriptional target of E2F.F-box蛋白Skp2:E2F的一个新的转录靶点。
Oncogene. 2006 Apr 27;25(18):2615-27. doi: 10.1038/sj.onc.1209286.
10
Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice.Id2在Rb突变小鼠中介导肿瘤起始、增殖和血管生成。
Mol Cell Biol. 2005 May;25(9):3563-74. doi: 10.1128/MCB.25.9.3563-3574.2005.